Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Anaplastic Oligodendroglioma: early-phase trial registry
5 of 13 indexed Anaplastic Oligodendroglioma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 5 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Anaplastic Oligodendroglioma: 13 US clinical trials tracked, 5 recruiting.
Anaplastic Oligodendroglioma is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition anaplastic-oligodendroglioma
OPEN 5 | RECR 38% | LATE 1 | EARLY 11 | RANK #1315 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Arterial Stiffness (38% recruiting · 13 trials)
Anaplastic Oligodendroglioma lists 5 open slots (38% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Anaplastic Oligodendroglioma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Anaplastic Oligodendroglioma is recruiting below its size-band peers.
5 of 13 indexed trials (38.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Anaplastic Oligodendroglioma research.
National Cancer Institute (NCI) accounts for 3 of 13 trials (23.1%). 11 distinct sponsors appear on at least one study for this condition label.
-
Most Anaplastic Oligodendroglioma trials plan to enrol fewer than 100 people.
Median target enrolment is 29 among the 13 trials that report a genuine target (sentinel values excluded). 9 of those (69.2%) plan for fewer than 100 participants.
-
Anaplastic Oligodendroglioma research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
NCT04541082
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
NCT04623931
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
NCT05698524
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
Columbia University
NCT06108206
Implantable Microdevice In Primary Brain Tumors
Oliver Jonas
NCT04135807
Pediatric Long-Term Follow-up and Rollover Study
Novartis Pharmaceuticals
NCT03975829
Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
NRG Oncology
NCT03180502
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
NCT04978727
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
NCT00995007
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
NCT02101905
AZD8055 for Adults With Recurrent Gliomas
National Cancer Institute (NCI)
NCT01316809
Cellular Immunotherapy Study for Brain Cancer
Jonsson Comprehensive Cancer Center
NCT01144247
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
City of Hope Medical Center
NCT01082926
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Anaplastic Oligodendroglioma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Anaplastic Oligodendroglioma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Anaplastic Oligodendroglioma page
13 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Anaplastic Oligodendroglioma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Anaplastic Oligodendroglioma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Anaplastic Oligodendroglioma condition card totals 13 registered trials; most-linked intervention Temozolomide; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.